Kura Oncology, Inc.
KURA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$9.62
KIRA · Stoqly’s AI analyst, in plain words
- Kura Oncology, Inc. had $67.5M of revenue in fiscal 2025, up 25.2% on the year before.
- Its operating margin was −449.9%, down 91.4 pts: of every 100 in sales, about −450 is left after running the business.
- Kura Oncology, Inc. lost $279M in fiscal 2025.
- Free cash flow was −$70.7M in fiscal 2025, −104.8% of revenue.
- Kura Oncology, Inc. has $658M more cash than debt.
Market cap
$855M
P/E
—
Revenue
$67.5M
Net income
−$279M
Free cash flow
−$70.7M
Operating margin
−449.9%
Kura Oncology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+25.2%
Yes. Sales grew 25.2% last year.
Does it make a profit?
−412.9%
No. It lost money last year.
Does profit turn into cash?
−104.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kura Oncology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Kura Oncology, Inc.
- CIK
- 0001422143
Kura Oncology, Inc. · KURA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | $53.9M | $67.5M |
| Revenue growth | — | — | — | — | 25.2% |
| Operating margin | — | — | — | −358.5% | −449.9% |
| Net income | −$130M | −$136M | −$153M | −$174M | −$279M |
| Net margin | — | — | — | −322.9% | −412.9% |
| Diluted EPS | −$1.97 | −$2.03 | −$2.08 | −$2.02 | −$3.18 |
| Cash | |||||
| Cash from operations | −$105M | −$110M | −$125M | $134M | −$64.1M |
| Capital expenditure | $1.1M | $0.6M | $0.2M | $0.5M | $6.6M |
| Free cash flow | −$106M | −$111M | −$125M | $134M | −$70.7M |
| FCF margin | — | — | — | 248.4% | −104.8% |
| Share count change | 25.0% | 1.0% | 9.3% | 17.7% | 1.8% |
| Debt and strength | |||||
| Cash and short-term investments | $518M | $438M | $424M | $727M | $667M |
| Debt incl. finance leases | — | $9.2M | $9.3M | $9.5M | $9.7M |
| Shareholders' equity | $507M | $420M | $397M | $414M | $174M |
| Current ratio | 23.3x | 18.6x | 12.3x | 9.5x | 6.1x |
| Interest coverage | — | −610.8x | −107.0x | −119.3x | −200.8x |
| Returns and quality | |||||
| Return on equity | −23.3% | −29.3% | −37.3% | −42.9% | −94.8% |
| Return on tangible equity | −25.8% | −32.3% | −38.4% | −42.1% | −160.0% |
| Piotroski F-score | — | — | 1 | 5 | 2 |
| Altman Z'' | — | 12.2 | 6.2 | 1.5 | −2.4 |
Insiders bought, 12 months
$2.4M
1 insider
Insiders sold, 12 months
$3.8M
7 insiders
Of sales under plans
67%
$2.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kura Oncology, Inc. · KURA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.62 a share, the company is worth $855M.
Source: SEC EDGAR XBRL filings (CIK 0001422143). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.